A5012403441- Asthma and respiratory diseases
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Diabetes Treatment and Management
- Chronic Kidney Disease and Diabetes
- Renal Diseases and Glomerulopathies
- Respiratory and Cough-Related Research
- Assisted Reproductive Technology and Twin Pregnancy
- Neonatal and Maternal Infections
- Health and Medical Studies
- Pneumonia and Respiratory Infections
- Obesity, Physical Activity, Diet
- Birth, Development, and Health
- Inhalation and Respiratory Drug Delivery
- Pharmaceutical studies and practices
- Systemic Lupus Erythematosus Research
- Global Maternal and Child Health
- HIV-related health complications and treatments
- Pharmacovigilance and Adverse Drug Reactions
- Nutrition, Health and Food Behavior
- Pneumocystis jirovecii pneumonia detection and treatment
- Ultrasound in Clinical Applications
- Viral gastroenteritis research and epidemiology
- Health Literacy and Information Accessibility
- Chemical Thermodynamics and Molecular Structure
- Maternal and Neonatal Healthcare
AstraZeneca (Sweden)
2019-2024
AstraZeneca (Brazil)
2020
Health First
2019
AstraZeneca (United Kingdom)
2019
GlaxoSmithKline (United Kingdom)
2016-2018
Age UK
2016-2017
KU Leuven
2015
University of Birmingham
2012-2013
Speech Pathology Australia
2013
Curtin University
2013
Globally, individuals with asthma tend to overrely on short-acting β2-agonists (SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying inflammation. Such relief-seeking behavior has been reinforced by long-standing treatment guidelines, which until recently recommended SABA-only use for immediate symptom relief. We aimed describe current burden of SABA among European within IN Asthma (SABINA) program. Prescription and/or dispensing data during 2006–2017 from...
Patients with asthma typically increase short-acting β2-agonists (SABA) use worsening symptoms. Excessive SABA may lead to a higher risk of adverse outcomes. We evaluated, in large population cohort, an association between inhaler and exacerbations healthcare utilization.As part the SABINA (SABA IN Asthma) global program, we conducted retrospective longitudinal observational study (SABINA I) using UK primary care electronic records (Clinical Practice Research Datalink; 2007-2017) from...
Sodium–glucose cotransporter 2 inhibitors such as dapagliflozin have been proven effective for slowing chronic kidney disease (CKD) progression in large outcomes trials that mainly included patients with higher levels of albuminuria. Understanding the real-world utilization and effectiveness these drugs among CKD lower albuminuria can inform clinical decision-making this population. Claims data from USA Japan were used to describe urinary albumin-to-creatinine ratio (UACR) < 200 mg/g who...
<b>As SABA overuse is associated with exacerbations and mortality, GINA no longer recommends only as a preferred reliever in asthma. A consistent pattern of high use from the SABINA programme would indicate global public health issue.</b>http://bit.ly/33XDrlb
Oral corticosteroids (OCS) are used to manage asthma exacerbations and severe, uncontrolled asthma, but OCS use is associated with adverse effects. We aimed describe the patterns of in real-world management patients western Europe. electronic medical records from databases France, Germany, Italy United Kingdom July 2011 through February 2018. Patients aged ≥12 years an diagnosis, at least one non-OCS medication within ±6 months available data ≥6 prior ≥90 days after cohort entry were...
Neonatal invasive disease caused by group B Streptococcus (GBS) represents a significant public health care concern globally. However, data related to burden, serotype distribution, and molecular epidemiology in China other Asian countries are very few specifically relative confined regions. The aim of this study was investigate the genetic characteristics GBS isolates recovered from neonates with during 2013-2014 at Guangzhou Changsha hospitals southern mainland China. We assessed capsular...
Some observational studies and randomized controlled trials (RCTs) have suggested an association between abacavir (ABC) use myocardial infarction (MI), whereas others not.This pooled analysis of 66 phase II-IV RCTs estimates exposure-adjusted incidence rates (IRs) relative (RRs) MI cardiovascular events (CVEs) in participants receiving ABC- non-ABC-containing combination antiretroviral therapy (cART). The primary included ABC-randomized with ≥48-week follow-up. Sensitivity analyses CVEs...
To improve understanding of real-world asthma treatment and inform physician education, we evaluated regional variation in prevalence oral corticosteroid (OCS) use across Germany.We developed a machine learning gradient-boosted tree model with IMS® Disease Analyzer electronic medical records, which cover 3% German patients. This had 91% accuracy predicting the presence chronic obstructive pulmonary disease. We applied to Longitudinal Prescription database, 82% national coverage, classify...
Oral corticosteroids (OCS) are often prescribed to patients with asthma that remains uncontrolled maintenance therapy. We performed a real-world analysis describe the geographic distributions of and OCS dispensed in Nordic countries. This observational, retrospective study examined patient-level data from nationally drug registries January December 2018 for individuals aged ≥12 years Denmark, Finland, Sweden. Using an algorithm based on treatment combinations defined by Global Initiative...
Introduction Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical presentation that involves multiple organ systems and may lead to damage increased risk of mortality. SLE associated high burden can include loss productivity employment reduced health-related quality life. The current standard care for primarily based on immunosuppression glucocorticoids toxicities poor tolerability. Anifrolumab, human monoclonal antibody type I interferon receptor subunit...
<h3>Introduction and objectives</h3> A better understanding of differences in asthma prevalence between regions will inform disease management treatment. To examine regional variations severe severe, uncontrolled asthma, we analyzed pharmacy records from the United Kingdom. <h3>Methods</h3> Data for 4,356,990 patients who received treatment fixed airflow obstruction during 2018 were extracted IQVIA's longitudinal database UK records, which included data 61% all 46% pharmacies. Indications...
Background In Australia, the regional prevalence of difficult-to-treat asthma is unknown. We aimed to describe variation in and oral corticosteroid (OCS) use.Methods this retrospective, observational, longitudinal study using data from March 2018–February 2019 NostraData database, prescriptions dispensed for obstructive airway disease were processed through a high-level algorithm identify patients with asthma. Difficult-to-treat was defined by ≥2 high-dosage inhaled corticosteroids plus...
Several observational studies and randomized controlled trials (RCTs) have suggested an association between abacavir (ABC) use myocardial infarction (MI) but others, including meta-analyses of clinical trial data, not. This updated meta-analysis estimates exposure-adjusted incidence rate (IR) relative (RR) MI coronary artery disease (CAD) in subjects receiving ABC non ABC-containing combination antiretroviral therapy (cART). Summary data from 52 Phase II-IV RCTs a previous were combined with...
Introduction: Characterization of regional variation in asthma treatment across Germany will improve understanding real-world therapy and inform physician education. We aimed to describe prevalence oral corticosteroid (OCS) use Germany.
<h3>Background</h3> Real-world evidence (RWE) on prescription medication use for systemic lupus erythematosus (SLE) is limited, and no real-world studies to date have investigated post-launch with anifrolumab, a type I interferon receptor inhibitor. ASTER the first multi-national, study examine patients SLE receiving standard therapy who initiate anifrolumab treatment as an add-on biologic. <h3>Objectives</h3> To describe design of ASTER. <h3>Methods</h3> (NCT05637112) longitudinal,...
Abstract Background and Aims In 2021, dapagliflozin was approved for the treatment of adults with chronic kidney disease (CKD) in Japan. This observational analysis is part multinational OPTIMISE-CKD study program aims to describe early utilization CKD following approval Japan, contextualized by contemporary management. Method Adult patients hospital claims data from Medical Data Vision Co. Ltd database (MDV; Tokyo, Japan) during 1 March 2020 – 28 February 2022 were included. defined as any...